BioSyntech Appoints Claude Leduc as a Chief Executive Officer.Business Editors LAVAL, Quebec--(BUSINESS WIRE)--Dec. 26, 2003 Mr. Serge Savard Serge Aubrey Savard, OC (born January 22, 1946 in Montreal, Quebec) is a former professional ice hockey defenceman, most famously with the Montreal Canadiens in the NHL. He is also a local businessman in Montreal, and is nicknamed the Senator. , Chairman of the Board of Directors of BioSyntech, is pleased to announce that Mr. Claude LeDuc was appointed as President and Chief Executive Officer of the Company. He will assume his new functions on March 1, 2004. Mr. LeDuc will bring an invaluable experience to BioSyntech with his 18 years' career in the Bio-pharma Industry; after a very successful (National Awards) pharmaceutical career in Sales at Syntex from 1986 to 1991, Mr. LeDuc then started his Biotech career with Serono in 1991 as a Regional Sales and Marketing Manager. In 1993, Mr. LeDuc joined Biomatrix in a new start-up where he had various successful roles from sales and marketing as Director of the Canadian business Canadian Business is the longest-publishing business magazine in Canada. It was founded in 1928 as The Commerce of the Nation, the organ of the Canadian Chamber of Commerce. The magazine was renamed Canadian Business in 1933. Unit to Business Development roles in Europe. After the Genzyme Biosurgery acquisition of Biomatrix in 2001, Mr. LeDuc was offered to assume various roles from the Genzyme Corporation Head Office in Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation). Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States. , first as Director of International Markets for the Orthopaedic Division and then as Director for Asia Pacific for the entire Biosurgery portfolio. Mr. LeDuc has full marketing and management responsibility for supporting and managing the Biosurgery distribution partners in all global assigned regions, as well as providing franchise support to the worldwide country managers. BioSyntech announced recently that its Quality Management System has been registered to ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. 9001:2000 and to ISO 13485:2001, recognizing compliance with international regulatory requirements for the conception and manufacturing of medical devices. ISO 13485 entitles BioSyntech to affix affix v. 1) to attach something to real estate in a permanent way, including planting trees and shrubs, constructing a building, or adding to existing improvements. the CE Marking to medical devices for European commercialization, through self-declaration of conformity. Prior examination of the product's conception file by a European Notified Body is required in the case of Class III medical devices. Mr LeDuc will bring to the company his many years of valuable expertise in the commercialization of orthopedic products around the world, thereby enabling the company to capitalize on Cap´i`tal`ize on` v. t. 1. To turn (an opportunity) to one's advantage; to take advantage of (a situation); to profit from; as, to capitalize on an opponent's mistakes s>. its newly acquired status. Mr Amine amine (əmēn`, ăm`ēn): see under amino group. amine Any of a class of nitrogen-containing organic compounds derived, either in principle or in practice, from ammonia (NH3). Selmani, the current CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. will leave his functions with Mr LeDuc's arrival to become the new Executive Chairman of the company. Mr Savard will resign as Chairman and remain a member of the Board of Directors. Mr Savard stated: "We are especially pleased that Mr LeDuc, who has been on our board of directors for more than a year, has now accepted to join the company on a full time basis. This is a strong vote of confidence in our technology from a person with an outstanding background in the industry." About BioSyntech - BioSyntech is a biotechnology company specializing in the discovery, development and manufacturing of regenerative medicine products and therapeutic delivery systems. BioSyntech's Quality Management System is registered to ISO 9001:2000 and ISO 13485:2001. For additional information, visit www.biosyntech.com. THIS PRESS RELEASE CONTAINS CERTAIN "FORWARD-LOOKING" STATEMENTS, AS DEFINED IN THE UNITED STATES United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. PRIVATE SECURITIES LITIGATION REFORM ACT The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and OF 1995 THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES. THERE CAN BE NO ASSURANCE THAT SUCH STATEMENTS WILL PROVE TO BE ACCURATE AND THE ACTUAL RESULTS AND FUTURE EVENTS COULD DIFFER MATERIALLY FROM MANAGEMENT'S CURRENT EXPECTATIONS. SUCH FACTORS ARE DETAILED FROM TIME TO TIME IN THE COMPANY'S FILINGS WITH THE REGULATORY AUTHORITIES HAVING JURISDICTION. NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion